Abstract

Clinical trial and postmarketing surveillance data for drugs used in treatment of attention deficit hyperactivity disorder were analyzed to determine the frequency of hallucinations and other psychotic side effects, in a study at the US Food and Drug Administration, and Department of Health and Human Services, Maryland.

Highlights

  • ADHD has received little attention until recently, isolated reports of cases are cited in the literature for the past 40 years

  • Clinical trial and postmarketing surveillance data for drugs used in treatment of attention deficit hyperactivity disorder were analyzed to determine the frequency of hallucinations and other psychotic side effects, in a study at the US Food and Drug Administration, and Department of Health and Human Services, Maryland

  • Hallucinations occurred during doubleblind treatment with every class of compound except Adderall XR, but psychosis/mania events were reported with open-label Adderall XR

Read more

Summary

Introduction

ADHD has received little attention until recently, isolated reports of cases are cited in the literature for the past 40 years. Clinical trial and postmarketing surveillance data for drugs used in treatment of attention deficit hyperactivity disorder were analyzed to determine the frequency of hallucinations and other psychotic side effects, in a study at the US Food and Drug Administration, and Department of Health and Human Services, Maryland. In a search of electronic databases of 49 randomized, controlled clinical pediatric trials, a total of 11 cases of psychosis/mania occurred during 743 person-years of double-blind treatment with these drugs. Hallucinations occurred during doubleblind treatment with every class of compound except Adderall XR, but psychosis/mania events were reported with open-label Adderall XR.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.